As the generic product is a copy of the original one (more or less modified), the generic producer in order to submit its product to the regulatory authority (for purposes of demonstrating bioequivalence) will rely on lawful reverse-engineering of the patented drug in order to understand how it was formulated. See Box 12, below, for details. While some countries may consider it unfair to let second comers take advantage of the investments made by data originators (“free riding”), other countries may regard as unfair to impose on financially weak generic producers, in particular those in poor developing countries or LDCs, the same requirements as those set up for multinational pharmaceutical companies, especially where the latter may at the same time benefit from patent protection on the respective substance and may already have entirely recouped their R&D investment in OECD country markets. Where this is the case, data originators no longer need to recoup any remaining costs, and there is a risk of over-compensating the data originator at the expense of generic price competition.